<DOC>
	<DOCNO>NCT01362374</DOCNO>
	<brief_summary>This open-label , multicenter , Phase Ib , dose-escalation study design assess safety , tolerability , pharmacokinetics oral GDC-0068 administer combination either docetaxel ( Arm A ) , oxaliplatin , leucovorin , 5-fluorouracil ( 5-FU ) ( mFOLFOX6 chemotherapy ) ( Arm B ) , paclitaxel ( Arm C ) , participant advance metastatic solid tumor standard therapy either exist proven ineffective intolerable . Arm D ass safety , tolerability , pharmacokinetics GDC-0068 administer combination enzalutamide participant metastatic castration-resistant prostate cancer ( CRPC ) . There two stage within arm study : dose-escalation stage ( Stage 1 ) cohort-expansion stage ( Stage 2 ) . In Stage 1 , approximately 3 6 cohort Arms A B 1 2 cohort Arms C D evaluate determine maximum tolerate dose ( MTD ) GDC-0068 give combination . Additional participant enrol Stage 2 ( cohort expansion ) , characterize safety tolerability GDC-0068 combination confirm potential recommend Phase II dose GDC-0068 regimen .</brief_summary>
	<brief_title>Safety Clinical Pharmacology GDC-0068 Combination With Docetaxel , Fluoropyrimidine Plus Oxaliplatin , Paclitaxel , Enzalutamide Participants With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 screen Histologically cytologically document advanced metastatic solid tumor establish therapy either exist proven ineffective intolerable Life expectancy great equal ( &gt; = ) 12 week Adequate hematologic end organ function For female participant childbearing potential male participant partner childbearing potential , agreement ( participant and/or partner ) use highly effective form contraception continue use duration study 4 month last dose study treatment ( female ) 6 month last dose study treatment ( male ) Prior anticancer therapy fulfill follow criterion : total three ( Arms A B ) two ( Arms C D ) prior cytotoxic chemotherapy regimen , highdose chemotherapy require stemcell support , irradiation &gt; =25 percent ( % ) bone marrowbearing area Treatment chemotherapy , hormonal therapy ( except hormone replacement therapy , oral contraceptive , gonadotropinreleasing hormone ( GnRH ) agonists antagonists prostate cancer ) , immunotherapy , biologic therapy , radiation therapy ( except palliative radiation bony metastasis ) , herbal therapy cancer therapy within 4 week prior initiation GDC0068 . Exceptions kinase inhibitor approve local regulatory authority , may use within 2 week prior initiation GDC0068 , provide clinicallyrelevant drugrelated toxicity completely resolve prior approval obtain Medical Monitor Palliative radiation bony metastasis within 2 week prior initiation GDC0068 History Type 1 Type 2 diabetes require regular medication Grade &gt; = 2 heart failure history unstable angina History clinically significant ventricular arrhythmia active ventricular arrhythmia require medication For Arm D : History seizure , unexplained loss consciousness , transient ischemic attack within 12 month enrollment , cerebral vascular accident , brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>